Navigation Links
U.S. Approves New Stem Cell Lines for Publicly Funded Research
Date:12/2/2009

13 added batches now available, many more to come, NIH director says,,

WEDNESDAY, Dec. 2 (HealthDay News) -- Thirteen stem cell lines have been added to the pool that scientists can use for taxpayer-funded research, and many more such lines will soon be made available, U.S. health officials announced Wednesday.

These are the first additional embryonic stem cell lines approved for research funded by the U.S. National Institutes of Health (NIH) since President Barack Obama last spring lifted restrictions on stem cell research that were imposed eight years ago by then-President George W. Bush.

"With these [lines] now becoming available for federally funded researchers, we believe it will speed up the process of investigating ways in which this remarkable new area of developmental biology can be explored," NIH director Dr. Francis S. Collins said during an afternoon teleconference Wednesday.

"The field has been waiting with bated breath for this announcement," one expert, Dr George Daley of Children's Hospital Boston, told the Associated Press. Eleven of the 13 stem cell lines approved Wednesday were developed at Children's, Collins noted, while the other two come from Rockefeller University in New York City.

Collins noted that over the past eight years, hundreds of embryonic stem cell lines have been created using private funds. "Many of them with more favorable characteristics for research purposes than the original ones approved by President Bush," he said.

Citing ethical issues, the Bush administration had limited federally funded research to about 21 stem cell lines already in existence in August 2001. That decision ignited a firestorm of controversy between those who advocated that human embryos should not be tampered with and those who viewed stem cell research as a potential pathway to curing a host of diseases.

Currently, 96 more human embryonic stem cell lines are under review to see if they meet the criteria for NIH-funded research, Collins said. Only one of the Bush-approved stem cell lines is among the 96 under consideration.

Recommendations to approve or reject 20 of these lines is expected on Friday, the NIH director said.

NIH policy still calls for new embryonic stem cell lines to be developed without taxpayer funding. "There is still a ban against the creation of new stem cell lines with federal funds," Collins stressed.

All the stem cell lines NIH is considering are derived from embryos left over from in vitro fertilization. These embryos would have been discarded, but the donors gave permission for them to be used in research, Collins noted.

At present, 31 NIH research grants, worth $21 million, are on hold, awaiting approval of these stem cell lines. With the approval of the 13 lines, researchers can begin to look at these lines to see if they are appropriate for their projects, Collins said.

Those projects include efforts to grow heart muscle, neurological stem cells and neurons. Other research is focusing on ways to produce more stem cells so they can be available in greater quantities to researchers, he said.

Embryonic stem cells are thought to be especially useful to medical science because they can be manipulated to become any type of body cell. Scientists hope to use these cells to create replacement tissues to treat a variety of diseases, such as diabetes, Parkinson's, spinal cord injuries and Alzheimer's disease.

"It is exciting to be able to say that -- after what has clearly been a time of some frustration on the part of the scientific community's inability to gain access with federal funds to cell lines that investigators wish to utilize -- that is now changing," Collins said.

More information

For more information on stem cells, visit the U.S. National Institutes of Health .



SOURCES: Dec. 2, 2009, teleconference with: Francis S. Collins, M.D., Ph.D., director, U.S. National Institutes of Health; Associated Press


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology: